Ginkgo Bioworks Holdings Inc (NYSE:DNA)
$ 9.66 -0.56 (-5.48%) Market Cap: 587.43 Mil Enterprise Value: 367.95 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Ginkgo Bioworks Holdings Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 05:45PM GMT
Release Date Price: $56.4 (-6.62%)
Unidentified Analyst

Hi, everyone. Thanks for coming. I'm from the life science tools and diagnostics team at JPMorgan. Welcome to the 2024 JPMorgan Healthcare Conference. So we're about to do about 20 minutes of questions and 20 minutes of Q&A.

And with that, I'd like to welcome CEO, Jason Kelly from Ginkgo Bioworks.

Jason Kelly
Ginkgo Bioworks Holdings, Inc. - Founder, CEO & Director

All right. Thank you. Sure, why not? Yes. Clap it in. Appreciate that. So I'm Jason Kelly, I'm the Co-Founder and CEO at Ginkgo Bioworks. I'm super excited to talk to you today about the progress Ginkgo has made in 2023, especially the work we've been doing in biopharma. I really consider this to be kind of a breakout year for us in that market. So excited to talk about that. And also I want to spend a little time on why I see Ginkgo as sort of general purpose infrastructure for biopharma R&D in the second half of the talk.

Before I get to that, I will be making forward-looking statements for a public company. When you have a chance, feel free to read

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot